 |
 |
 |
 |
 |
Arizona Cancer Center researcher announces results of clinical trial: Up to 95 percent reduction in colon cancer risk
SEE RELATED KUAT STORY | CLICK HERE
Researchers announced today that the combination of a low dosage of the targeted agent difluoromethylornithine (DFMO) and sulindac, a non-steroidal anti-inflammatory drug (NSAID), has been shown to reduce the risk of recurrent colorectal polyps, a precursor to colon cancer, by up to 95 percent with minimal toxicity.
“Combination chemoprevention with DFMO and sulindac can substantially reduce colon polyp recurrence, especially those polyps associated with the greatest risk of colorectal cancer,” says Eugene W. Gerner, Ph.D, director of the Arizona Cancer Center’s Gastrointestinal (GI) Cancer Program and the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in GI Cancers at the University of Arizona College of Medicine. Dr. Gerner is also a member of the BIO5 Institute at the University of Arizona.
Dr. Gerner and Frank Meyskens, MD, director of the Chao Family Cancer Center at the University of California at Irvine, announced their research results earlier today at the annual meeting of the American Association for Cancer Research (AACR) in San Diego. The research results also were published online this week in the inaugural issue of the AACR’s new journal, Cancer Prevention Research.
“The spectacular clinical results reported by Meyskens and colleagues in the lead article of this very first issue of this new AACR journal on cancer prevention represent a landmark advance in efforts to stop the current worldwide epidemic of cancer deaths,” says Michael B. Sporn, professor of pharmacology and toxicology at Dartmouth Medical School, Hanover, New Hampshire.
In earlier studies, the research team had established a safe and well-tolerated dose of DFMO, a specific inhibitor polyamine synthesis, that was 1/50th of what would typically be used to treat advanced cancers. By combining this reduced dose of DFMO with sulindac, researchers believed they could achieve a significant clinical effect with reduced toxicity.
“There is a great hope that we will be able to prevent colon cancer effectively using this method. We had not been able to do this before due to the high toxicity of available therapies. DFMO is a targeted agent that represents a new treatment paradigm,” says Dr. Meyskens.
For the current study, researchers enrolled 375 patients who had a history of at least one colorectal polyp within the previous five years. Patients were randomly assigned to either a combination of 500 mg of daily DFMO and 150 mg of sulindac, or placebo. Patients were followed for three years to measure adenoma recurrence.
Overall, the combination treatment reduced the risk of a recurrent adenoma from 41.1 percent in the placebo group to 12.3 percent with treatment, a 70 percent reduction.
When researchers measured advanced adenomas only, the rate was 8.5 percent in the placebo group compared with 0.7 percent in the treatment group, a 92 percent reduction. For adenomas larger than one centimeter, the rate was 7 percent in the placebo group compared with 0.7 percent in the treatment group, a 90 percent reduction. Among patients who had previously had more than one adenoma, the rate of subsequent adenomas was 13.2 percent in the placebo group compared with 0.7 percent in the treatment group, a 95 percent reduction.
The rate of reduction was so pronounced that the trial’s independent data and safety monitoring board stopped the trial early.
An analysis of side effects and toxicity found no significant difference between the treatment and placebo groups. There was no significant difference in side effects requiring an overnight hospitalization, gastrointestinal side effects, cardiovascular side effects, or hearing loss between the two groups.
“Recent studies have provided proof of principle that chemoprevention of colorectal cancer through the use of natural or synthetic agents to prevent or suppress the progression of precursor lesions (colorectal adenomas) is possible, but positive effects have been modest and have been associated with unacceptable toxicities,” says Robert S. Bresalier, M.D., professor of medicine and distinguished professor in GI oncology for The University of Texas MD Anderson Cancer Center.
“Dr. Meyskens and his colleagues have employed sound biological principles and a methodical approach to demonstrate that a very substantial reduction in new adenoma formation in at-risk individuals is possible without substantial risk using DFMO and sulindac,” Dr. Bresalier continues. “I look forward to seeing the results of additional long-term trials with these agents.”
“Our research was funded by several grants, including the GI SPORE sponsored by the National Cancer Institute. We are very gratified that our study has produced such promising results,” says Dr. Gerner. The Arizona Cancer Center is one of only five institutions nationwide to receive a GI SPORE; the others include Harvard, Johns Hopkins, the University of North Carolina, and Vanderbilt University. Originally funded in 2002, the GI SPORE is the largest new grant awarded to the University of Arizona College of Medicine in the past 10 years. It was renewed in 2007 for another five years and funded at $12 million.
Media interviews and B-roll opportunities: Dr. Gerner is available for telephone interviews immediately and will be available for on-camera interviews on Wednesday, April 16, and the rest of the week. A DVD with B-roll of Dr. Gerner’s laboratory is also available. Contact Donna Breckenridge at 626-2277 to arrange for interviews.NOTE: There are currently no colon cancer or colon cancer prevention clinical trials using DFMO enrolling subjects at this time. Please check back for future updates.
To view a journal article about this study, click here.
To find out more about GI research going on at the Arizona Cancer Center, click here.
The Arizona Cancer Center is the state’s premier National Cancer Institute-designated comprehensive cancer center. With multiple primary research sites in Tucson and in Phoenix, Mesa, Scottsdale and Sun City, the Center has 300 world-class physician and scientist members, working to prevent and cure cancer.
Webmaster | Privacy Policy | Disclaimer
Arizona Cancer Center :: 1515 North Campbell Ave Tucson, AZ 85724-5024
Copyright ABOR :: All rights reserved.
|
